Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

The European Union has reached a provisional agreement on the Critical Medicines Act (CMA) on May 13, 2026, marking a major shift in pharmaceutical policy toward supply chain sovereignty. The framework aims to reduce dependency on non-EU imports, strengthen domestic
As artificial intelligence rapidly embeds itself across pharmaceutical manufacturing, R&D, and quality systems, it is no longer just driving efficiency, it is exposing a critical divide in digital maturity. Across GMP-regulated environments, AI is revealing hidden weaknesses in data integrity,